Zaleska Karolina
Radiobiology Laboratory in the Medical Physics Department, Greater Poland Cancer Centre, Poznan, Poland.
Rep Pract Oncol Radiother. 2014 Nov 26;20(2):79-86. doi: 10.1016/j.rpor.2014.10.009. eCollection 2015 Mar-Apr.
The aim of this study was to review the current knowledge about involvement of microRNAs in breast cancer, and their potential in the clinic, published in scientific journals searched in Pubmed/Medline database until March 2014.
MicroRNAs (miRNAs) are a family of 21-25 nucleotide small RNAs molecules. Currently, it is well known that miRNA plays a key role in all cellular processes of the organism including tumour initiation and progression. Many studies have shown that circulating miRNAs are attractive, easily detectable tumour biomarkers. Breast cancer is one of the most common cancers in the world. It is clinically established that different subtypes may respond differently to therapies, give metastases and present drug resistance. MicroRNAs have a potential as diagnostic, prognostic and therapeutic tools in breast cancer.
Molecular knowledge is crucial for choosing the most effective therapy for individual patients. MicroRNAs holds a great potential in anticancer therapy.
本研究旨在回顾截至2014年3月在Pubmed/Medline数据库检索的科学期刊上发表的关于微小RNA参与乳腺癌的当前知识及其在临床中的潜力。
微小RNA（miRNA）是一类由21 - 25个核苷酸组成的小RNA分子。目前，众所周知，miRNA在生物体的所有细胞过程中发挥关键作用，包括肿瘤的发生和发展。许多研究表明，循环miRNA是有吸引力的、易于检测的肿瘤生物标志物。乳腺癌是世界上最常见的癌症之一。临床上已证实，不同亚型对治疗的反应可能不同，会发生转移并出现耐药性。微小RNA在乳腺癌的诊断、预后和治疗工具方面具有潜力。
分子知识对于为个体患者选择最有效的治疗方法至关重要。微小RNA在抗癌治疗中具有巨大潜力。
